Advancements in Dengue Vaccines: Butantan-DV and TAK-003 Show Promising Results

The current epidemiological situation of dengue in Latin America and around the world is a cause of great concern. The disease, caused by the dengue virus (DENV), is already considered endemic in tropical and subtropical regions around the world. The World Health Organization (WHO) identifies it as one of the ten major health threats, underlining its rapidly changing epidemiology and great threat to public health, especially in tropical and sub-tropical regions. tropical. The overall incidence of disease is important; with approximately 50% of the world’s population at risk of contracting the disease. According to the WHO, up to 3.2 million cases are reported every year in the entity’s member countries.^[1]

The development of effective vaccines against dengue is the subject of extensive research and several promising candidates have already emerged. One of the advances in this situation is the vaccine Butantan-DV, similar to TV003, developed by the Butantan Institute in São Paulo. Buttons-Dv is a live attenuated quadrivalent vaccine designed to induce a balanced and long-lasting antibody response against the four dengue virus serotypes (DENV-1, DENV-2, DENV-3 and DENV-4). Clinical trials demonstrated the safety and immunity of Butantan-DV in adults in Brazil, with strong neutralizing antibody responses against all dengue serotypes after vaccination. This is a major advance in the development of dengue vaccines, offering the potential for broad-spectrum protection against multiple serotypes of the virus.^[2]

Another specific vaccine is TAK-003 (Qdeng) with live attenuated viruses, which have shown efficacy against several serotypes of the dengue virus. Other quadrivalent virus vaccine candidates, such as Dengvaxia and other TV003 analogues have shown efficacy in inducing neutralizing antibodies against various virus serotypes. These vaccine agents have advanced to phase 3 clinical trials and have shown promising results in terms of safety, immunogenicity, and efficacy.^[3,4] Are you aware of the latest studies on new dengue vaccines? Test your knowledge with our Mini-Clinical exam.

Medscape © 2024 WebMD, LLC

The above opinions are those of the author and do not necessarily reflect the opinions of WebMD or Medscape.

Cite this article: Mini clinical study: Dengue vaccines – Medscape – April 18, 2024.